# 1st Gen Model Abbott Laboratories Pharmaceutical preparations
- $48.91Last close price
at 26-jun-2017 -
Subscribe >>
Deal exit on
June 27, 2017 Deal entry on
June 27, 2017 - 1.62%Expected margin
- 49.18% successful of 61 deals
ABT
Model's trade recommendations -8.06% Return for period
-10.28% Annual return
$85.17B Market Cap
β 1.08
ABT
Model (following trade recommendations)ABT
Underlying stockS&P 500
Index- 1.06 (2.16%) Div (Yield)
- STRONG BUY Analysts consensus recommendation
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.
Industry sector: Medical
Sector classification: Pharmaceutical preparations
Deep Learning based analysis and prediction model for Abbott Laboratories (ABT) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since April 29, 2015.
Market data for ABT model training are being downloaded from the Quandl premium datasets on a daily basis.
Model is being retrained on a daily basis.
| Float | 1722M |
| P/E | 21.62 |
| Shares Outstanding | 1735M |
| % Held by Insiders | 0.76% |
| % Held by Institutions | 71.10% |
| EPS (last reported FY) | $2.20 |
| EPS (last reported Q) | $0.48 |
| EPS, estimated (last reported Q) | $0.43 |
| Total revenues | $21 B |
| Net income | $1 B |